These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28992755)

  • 1. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
    Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
    Mehta A; Sequiera GL; Ramachandra CJ; Sudibyo Y; Chung Y; Sheng J; Wong KY; Tan TH; Wong P; Liew R; Shim W
    Cardiovasc Res; 2014 Jun; 102(3):497-506. PubMed ID: 24623279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
    Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
    Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
    De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
    Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAVIN1-Mediated hERG Dynamics: A Novel Mechanism Underlying the Interindividual Variability in Drug-Induced Long QT.
    Al Sayed ZR; Pereira C; Le Borgne R; Viaris de Lesegno C; Jouve C; Pénard E; Mallet A; Masurkar N; Loussouarn G; Verbavatz JM; Lamaze C; Trégouët DA; Hulot JS
    Circulation; 2024 Aug; 150(7):563-576. PubMed ID: 38682330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene- and variant-specific efficacy of serum/glucocorticoid-regulated kinase 1 inhibition in long QT syndrome types 1 and 2.
    Giannetti F; Barbieri M; Shiti A; Casini S; Sager PT; Das S; Pradhananga S; Srinivasan D; Nimani S; Alerni N; Louradour J; Mura M; Gnecchi M; Brink P; Zehender M; Koren G; Zaza A; Crotti L; Wilde AAM; Schwartz PJ; Remme CA; Gepstein L; Sala L; Odening KE
    Europace; 2023 May; 25(5):. PubMed ID: 37099628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R534C mutation in hERG causes a trafficking defect in iPSC-derived cardiomyocytes from patients with type 2 long QT syndrome.
    Mesquita FCP; Arantes PC; Kasai-Brunswick TH; Araujo DS; Gubert F; Monnerat G; Silva Dos Santos D; Neiman G; Leitão IC; Barbosa RAQ; Coutinho JL; Vaz IM; Dos Santos MN; Borgonovo T; Cruz FES; Miriuka S; Medei EH; Campos de Carvalho AC; Carvalho AB
    Sci Rep; 2019 Dec; 9(1):19203. PubMed ID: 31844156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.
    Sala L; Yu Z; Ward-van Oostwaard D; van Veldhoven JP; Moretti A; Laugwitz KL; Mummery CL; IJzerman AP; Bellin M
    EMBO Mol Med; 2016 Sep; 8(9):1065-81. PubMed ID: 27470144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias.
    Brandão KO; van den Brink L; Miller DC; Grandela C; van Meer BJ; Mol MPH; de Korte T; Tertoolen LGJ; Mummery CL; Sala L; Verkerk AO; Davis RP
    Stem Cell Reports; 2020 Nov; 15(5):1127-1139. PubMed ID: 33176122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
    O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
    Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
    Ma D; Wei H; Zhao Y; Lu J; Li G; Sahib NB; Tan TH; Wong KY; Shim W; Wong P; Cook SA; Liew R
    Int J Cardiol; 2013 Oct; 168(6):5277-86. PubMed ID: 23998552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
    Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
    J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
    Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
    Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
    Lee HA; Hyun SA; Byun B; Chae JH; Kim KS
    PLoS One; 2018; 13(4):e0195577. PubMed ID: 29630634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues.
    Veldhuizen J; Mann HF; Karamanova N; Van Horn WD; Migrino RQ; Brafman D; Nikkhah M
    Sci Adv; 2022 Dec; 8(50):eabq6720. PubMed ID: 36525500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Efficacy of Mexiletine for Long QT Syndrome Type 2: Evidence From Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes, Transgenic Rabbits, and Patients.
    Crotti L; Neves R; Dagradi F; Musu G; Giannetti F; Bos JM; Barbieri M; Cerea P; Giovenzana FLF; Torchio M; Mura M; Gnecchi M; Conte G; Auricchio A; Sala L; Odening KE; Ackerman MJ; Schwartz PJ
    Circulation; 2024 Aug; 150(7):531-543. PubMed ID: 38939955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.
    Shinozawa T; Nakamura K; Shoji M; Morita M; Kimura M; Furukawa H; Ueda H; Shiramoto M; Matsuguma K; Kaji Y; Ikushima I; Yono M; Liou SY; Nagai H; Nakanishi A; Yamamoto K; Izumo S
    Stem Cell Reports; 2017 Feb; 8(2):226-234. PubMed ID: 28111276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2.
    Mura M; Mehta A; Ramachandra CJ; Zappatore R; Pisano F; Ciuffreda MC; Barbaccia V; Crotti L; Schwartz PJ; Shim W; Gnecchi M
    Int J Cardiol; 2017 Aug; 240():367-371. PubMed ID: 28433559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.